T
Tomoya Yokota
Publications - 148
Citations - 2445
Tomoya Yokota is an academic researcher. The author has contributed to research in topics: Cancer & Chemoradiotherapy. The author has an hindex of 22, co-authored 130 publications receiving 1865 citations.
Papers
More filters
Journal ArticleDOI
BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
Tomoya Yokota,Takashi Ura,N. Shibata,Daisuke Takahari,Kohei Shitara,M. Nomura,C. Kondo,Ayako Mizota,Setsuo Utsunomiya,Kei Muro,Yasushi Yatabe +10 more
TL;DR: Presence of mutated BRAF is one of the most powerful prognostic factors for advanced and recurrent CRC, and the KRAS13 mutation showed a trend towards poor OS in patients with advanced and recurring CRC.
Journal ArticleDOI
Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer
Tomoya Yokota,Ken Kato,Yasuo Hamamoto,Yasuhiro Tsubosa,Hirofumi Ogawa,Yoshinori Ito,Hiroki Hara,Takashi Ura,Takashi Kojima,Keisho Chin,Shuichi Hironaka,Takayuki Kii,Yasushi Kojima,Yasunori Akutsu,Hisayuki Matsushita,Kentaro Kawakami,Keita Mori,Yushi Nagai,Chika Asami,Yuko Kitagawa +19 more
TL;DR: Chemoselection with DCF-ICT followed by CS as a multidisciplinary treatment strategy showed promising signs of tolerability and efficacy in patients with locally advanced unresectable SCC of the oesophagus.
Journal ArticleDOI
Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX
Kohei Shitara,Keitaro Matsuo,Daisuke Takahari,Tomoya Yokota,Yoshitaka Inaba,Hidekazu Yamaura,Yozo Sato,Mina Najima,Takashi Ura,Kei Muro +9 more
TL;DR: Both mild and severe neutropaenia during chemotherapy are associated with improved survival in patients with MCRC and Prospective trials are required to assess whether dosing adjustments based on neutrop aenia may improve chemotherapy efficacy.
Journal ArticleDOI
Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy
Kohei Shitara,Keitaro Matsuo,Isao Oze,Ayako Mizota,Chihiro Kondo,Motoo Nomura,Tomoya Yokota,Daisuke Takahari,Takashi Ura,Kei Muro +9 more
TL;DR: Neutropenia or leukopenia experienced during chemotherapy is associated with improved survival in patients with advanced cancer or hematological malignancies undergoing chemotherapy, and future prospective analyses designed to investigate the potential impact of chemotherapy dose adjustment coupled with monitoring of neutropenian on survival are warranted.
Journal ArticleDOI
A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141.
Naomi Kiyota,Yasuhisa Hasegawa,Shunji Takahashi,Tomoya Yokota,Chia Jui Yen,Shigemichi Iwae,Yasushi Shimizu,Ruey Long Hong,Masahiro Goto,Jin Hyoung Kang,Wing Sum Kenneth Li,Robert L. Ferris,Maura L. Gillison,Yoshinobu Namba,Manish Monga,Mark Lynch,Makoto Tahara +16 more
TL;DR: Nivolumab demonstrated a survival advantage compared with conventional treatments in Asian patients with platinum-refractory recurrent or metastatic SCCHN, and was well tolerated.